J Dig Cancer Res.  2022 Dec;10(2):82-91. 10.52927/jdcr.2022.10.2.82.

Drug Discovery Platform Using Organoids

• Maeng JE
• Kim SC
• Song MH
• Jeong N
• Ku JL

• KMID: 2536425
• DOI: http://doi.org/10.52927/jdcr.2022.10.2.82

Abstract

Gastrointestinal cancer accounts for one-third of the overall cancer occurrence worldwide. Pancreatic ductal adenocarcinoma (PDAC) is a type of gastrointestinal cancer that is known to be one of the most fatal among all cancer types, with a 5-year survival rate of less than 8%. Chemotherapy combined with surgical resection is its probable curative option. However, surgery is accessible for only 10–15% of patients diagnosed with PDAC. Organoids show self-organizing capacities and resemble the original tissue in terms of morphology and function. Organoids can also be cultured with high effectiveness from tumor tissues derived from each patient, making them an extremely fitting model for translational uses and improving personalized cancer medicine. Enhancing drug screening platforms is necessary to apply personalized medicinebased organoids in clinical settings.

Keyword

Pancreatic neoplasm; Gastrointestinal neoplasms; Organoids; Drug evaluation; High-throughput nucleotide sequencing